Search results
Results From The WOW.Com Content Network
The Nun Study of Aging and Alzheimer's Disease is a continuing longitudinal study, begun in 1986, to examine the onset of Alzheimer's disease. [1] [2] David Snowdon, an Epidemiologist and the founding Nun Study investigator, started the Nun Study at the University of Minnesota, later transferring the study to the University of Kentucky in 1990. [3]
Alzheimer’s disease, the most common form of dementia, affects almost 7 million people in the United States alone. Following a diagnosis, it is difficult to predict how the disease will progress ...
Alzheimer's financial burden on society is large, with an estimated global annual cost of US$1 trillion. [14] It is ranked as the seventh leading cause of death worldwide. [30] Given the widespread impacts of Alzheimer's disease, both basic-science and health funders in many countries support Alzheimer's research at large scales.
The impact of Alzheimer's disease on individuals and their families is profound, making ongoing research and promising developments in treatments like lecanemab incredibly important. The strides being made in understanding the physiological aspects of the disease, as well as the potential treatments, provide hope for millions of people ...
Some people, however, can live up to 20 years after their diagnosis. Different types of dementias, like Alzheimer’s disease and vascular dementia, have different prognoses, with some causing ...
The bacteria invade nerve tissue in the brain, increasing the permeability of the blood–brain barrier and promoting the onset of Alzheimer's. Individuals with a plethora of tooth plaque risk cognitive decline. [158] Poor oral hygiene can have an adverse effect on speech and nutrition, causing general and cognitive health decline.
A new Alzheimer's drug is being hailed as a "turning point" in the fight against the disease, with researchers saying it marks the beginning of a "new era where Alzheimer's could become treatable".
The Guardian says the paper was "highly influential" and calls it "one of the most cited pieces of Alzheimer's disease research in the last two decades", writing that it has "dominated the field" of research. [20] The Atlantic likens publication in Nature to a "career high-water mark", reflecting especially important findings. [22]